| Market Cap | 9.99M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -10.52M | Forward P/E | -6.86 | EPS next Y | - | 50D Avg Chg | -42.00% |
| Sales | 152.43k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -55.00% |
| Dividend | N/A | Price/Book | 5.93 | EPS next 5Y | - | 52W High Chg | -84.00% |
| Recommedations | 3.00 | Quick Ratio | 0.03 | Shares Outstanding | 10.56M | 52W Low Chg | 26.00% |
| Insider Own | 26.97% | ROA | -42.67% | Shares Float | 6.80M | Beta | 0.77 |
| Inst Own | 2.43% | ROE | -191.96% | Shares Shorted/Prior | 532.98K/105.85K | Price | 3.02 |
| Gross Margin | -98.15% | Profit Margin | - | Avg. Volume | 767,356 | Target Price | - |
| Oper. Margin | -90,605.55% | Earnings Date | May 13 | Volume | 423,408 | Change | -16.34% |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
